Category: Life Sciences
Global Life Sciences
-
Prescription Drugs
... CAGR of 5.7% over the analysis period 2024-2030. Generic Drugsone of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$498.0 Billion by the end of the analysis period. ... Read More
-
Carotenoids
... 3.8% over the analysis period 2024-2030. Beta-Carotene, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in ... Read More
-
Anti-Obesity Drugs
... CAGR of 8.7% over the analysis period 2024-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis ... Read More
-
Medical Membranes
... CAGR of 7.7% over the analysis period 2024-2030. Ultrafiltration Technology, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Vascular Grafts
... CAGR of 7.2% over the analysis period 2024-2030. Endovascular Aneurysm Repair (EVAR) Indication, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.6 Billion by the end ... Read More
-
Orthopedic Braces & Support, Casting and Splints
... expected to reach US$10.1 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Orthopedic Braces & Supports, one of the segments analyzed in the report, is expected to record a ... Read More
-
Surgical Gloves
... CAGR of 6.6% over the analysis period 2024-2030. Nitrile Gloves, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.4 Billion by the end of the analysis ... Read More
-
Humanized Mouse and Rat Model
... Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Humanized Rat Models, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$13.6 ... Read More
-
Hybrid Operating Rooms
... at a CAGR of 12.2% over the analysis period 2024-2030. Intraoperative Diagnostic Imaging Systems, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Cosmetic Antioxidants
... CAGR of 5.0% over the analysis period 2024-2030. Vitamins, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$54.2 Million by the end of the analysis period. ... Read More
-
Genotyping
... 15.3% over the analysis period 2024-2030. Polymerase Chain Reaction (PCR) Technology, one of the segments analyzed in the report, is expected to record a 15.9% CAGR and reach US$10.9 Billion by the end of the ... Read More
-
Healthcare Mobility Solutions
... at a CAGR of 18.9% over the analysis period 2024-2030. Mobile Devices, one of the segments analyzed in the report, is expected to record a 17.6% CAGR and reach US$120.5 Billion by the end of ... Read More
-
Hemodialysis
... 4.7% over the analysis period 2024-2030. Hemodialysis Services, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$80.1 Billion by the end of the analysis period. Growth ... Read More
-
Hemophilia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Hemophilia A Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$21.3 Billion by the end of the ... Read More
-
Herpes Marker Testing
... at a CAGR of 4.9% over the analysis period 2024-2030. Antibody / Antigen-Based Kits, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$332.9 Million by the ... Read More
-
High Pressure Pumps
... at a CAGR of 3.5% over the analysis period 2024-2030. Dynamic Pumps, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Hemodialysis Catheters
... CAGR of 4.2% over the analysis period 2024-2030. Cuffed Tunneled Catheters, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$542.7 Million by the end of the ... Read More
-
Hepatitis B Vaccines
... at a CAGR of 4.4% over the analysis period 2024-2030. Combination Vaccines, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.6 Billion by the end of ... Read More
-
Cell Dissociation
... CAGR of 11.6% over the analysis period 2024-2030. Enzymatic Dissociation Products, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$506.9 Million by the end of the ... Read More
-
Cell Expansion
... CAGR of 14.8% over the analysis period 2024-2030. Cell Expansion Consumables, one of the segments analyzed in the report, is expected to record a 16.0% CAGR and reach US$42.4 Billion by the end of the ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by ... Read More
-
Chiral Chemicals
... CAGR of 6.2% over the analysis period 2024-2030. Traditional Separation Method, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$50.8 Billion by the end of the ... Read More
-
Clot Management Devices
... at a CAGR of 4.6% over the analysis period 2024-2030. Percutaneous Thrombectomy Devices, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.1 Billion by the end ... Read More
-
Cold Pressed Juices
... at a CAGR of 5.6% over the analysis period 2024-2030. Organic Cold Pressed Juices, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$2.3 Billion by the ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
Research Assistance
